Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial-Reference-Cited by-同舟云学术

Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

Published:2011-02-08 Issue:3 Volume:50 Page:344-352
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Purmonen Timo T.,Pänkäläinen Emma,Turunen Juha H. O.,Asseburg Christian,Martikainen Janne A.

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2011.553841

Reference29 articles.

1. HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues

2. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

3. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-20

2. Plasma microRNA-195, −34c, and − 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients;Toxicology and Applied Pharmacology;2023-09

3. Immunological Landscape of HER-2 Positive Breast Cancer;Cancers;2022-06-28

4. Evaluation of the anti-tumor activities of Sulfonylurea Derivatives;2022-01-11

5. How We Treat HER2-Positive Metastatic Breast Cancer;Indian Journal of Medical and Paediatric Oncology;2021-08